ライフサイエンスコーパス: cancer patient

1 are predictive of survival for human breast cancer patients.

2 , and correlated with poor prognosis in lung cancer patients.

3 RNA 3' modifications in HEK293T cells and in cancer patients.

4 or the major challenge of effectively curing cancer patients.

5 treme weight loss in animals and cachexia in cancer patients.

6 nt of this severe morbidity in head and neck cancer patients.

7 ouse model and more pain experienced by oral cancer patients.

8 to chemotherapy, shortens life expectancy of cancer patients.

9 has had a devastating impact on the care of cancer patients.

10 potentially improve the clinical outcomes of cancer patients.

11 quencing for treatment decisions in advanced cancer patients.

12 in metastatic castration-resistant prostate cancer patients.

13 ely lead to prolonged treatment responses in cancer patients.

14 tainty of drug efficacy and heterogeneity of cancer patients.

15 vely affect long-term survival of esophageal cancer patients.

16 sentinel nodes (SNs) of individual prostate cancer patients.

17 Immunotherapy fails to cure most cancer patients.

18 ficant unmet clinical need for head and neck cancer patients.

19 biomarker to assess oxidative stress in oral cancer patients.

20 tadine to improve outcomes for head and neck cancer patients.

21 rapies induce early decline in heart mass in cancer patients.

22 s with poor clinical outcome in human breast cancer patients.

23 base was utilised to identify the colorectal cancer patients.

24 MCP-1/CCR-2 axis that could benefit ovarian cancer patients.

25 cle fiber cross-sectional area in pancreatic cancer patients.

26 Metastasis is the primary cause of death of cancer patients.

27 l lines and primary tumor cells from bladder cancer patients.

28 whether APE2 is differentially expressed in cancer patients.

29 ranslatable predictive cancer biomarkers for cancer patients.

30 educe metastasis and improve the survival of cancer patients.

31 ntify various sphingolipid species in breast cancer patients.

32 lecular subtypes and poor survival in breast cancer patients.

33 ctice as an effective therapeutic option for cancer patients.

34 assay is applicable to clinical samples from cancer patients.

35 ith longer survival in metastatic pancreatic cancer patients.

36 gs in the prevention or treatment of GVHD in cancer patients.

37 ted with improved overall survival in breast cancer patients.

38 et almost exclusively found in advanced lung cancer patients.

39 n be enhanced by PARG inhibition in prostate cancer patients.

40 criptional programs commonly dysregulated in cancer patients.

41 ypercarbia/hypocarbia - conditions common in cancer patients.

42 th STAT3 and EGFR inhibitors, for pancreatic cancer patients.

43 the most important cause of death in breast cancer patients.

44 tor in the prognosis and treatment of breast cancer patients.

45 ll responses can induce antitumor effects in cancer patients.

46 markers linking smoking and survival of lung cancer patients.

47 istant metastasis and poor outcome in breast cancer patients.

48 application has been limited to a subset of cancer patients.

49 reasingly appealing therapeutic strategy for cancer patients.

50 ificantly higher than those of squamous cell cancer patients.

51 associated with decreased survival of breast cancer patients.

52 cle fiber cross-sectional area in pancreatic cancer patients.

53 order to fully meet the therapeutic needs of cancer patients.

54 s permanent impairment of quality of life in cancer patients.

55 mains the major side effect, particularly in cancer patients.

56 oduction of PROTACs into clinical trials for cancer patients.

57 and detectable in blood and tumors from lung cancer patients.

58 ated with improved immunotherapy response in cancer patients.

59 les (~1 copy) in blood samples of pancreatic cancer patients.

60 rohibitive contraindications, including most cancer patients.

61 y correlates with brain metastases in breast cancer patients.

62 s could have broad clinical implications for cancer patients.

63 tumor can be detected in the venous blood of cancer patients.

64 s similar to escape mechanisms seen in human cancer patients.

65 s associated with reduced survival of breast cancer patients.

66 diation dosimetry study of (68)Ga-FAPI-46 in cancer patients.

67 rategies to improve the prognosis for breast cancer patients.

68 um-based drugs on plasma S1P levels in human cancer patients.

69 ated with the overall survival of pancreatic cancer patients.

70 effective neoadjuvant therapy for pancreatic cancer patients.

71 aling prognostic and diagnostic approach for cancer patients.

72 i-HER2-VHH1 in healthy volunteers and breast cancer patients.

73 play significant prognostic roles in breast cancer patients.

74 es with poor prognosis in ER-positive breast cancer patients.

75 resistance in PDXs from NAC-resistant breast cancer patients.

76 t common source of neurological morbidity in cancer patients.

77 stewardship that has not been described for cancer patients.

78 was also investigated in a cohort of 72 oral cancer patients.

79 Methods: Fifty-six prostate cancer patients (18 before prostatectomy and 38 with bio

80 Danish cohort study of premenopausal breast cancer patients (2002-2011), for which conventional anal

81 me in estrogen receptor (ER)-negative breast cancer patients, a population with limited available tre

82 Data from cancer patients admitted to ICUs for sepsis or septic sh

83 assess trends in survival rates over time in cancer patients admitted to the ICU for sepsis or septic

84 Tumor DNA circulates in the plasma of cancer patients admixed with DNA from noncancerous cells

85 hibitor in pan T cells, isolated from breast cancer patients, also increases cytotoxic CD8(+) T cells

86 n of Mcl-1 TMD somatic mutations detected in cancer patients alters the TMD interaction pattern to pr

87 n for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized

88 reference peptide in hemoglobin from 18 oral cancer patients and 15 healthy control subjects.

89 ociation studies comprising 2,039 pancreatic cancer patients and 32,592 controls in the Japanese popu

90 Consortium containing 68,521 invasive breast cancer patients and 54,865 controls.

91 ing samples collected pre-diagnosis from ten cancer patients and 69 controls.

92 the present study, exome sequencing data of cancer patients and analysis of distinct melanoma and bl

93 sity neutrophils (LDN) has been described in cancer patients and associated with tumor-supportive pro

94 anically-activated calcium pathway in breast cancer patients and by KRas activation reveal signaling

95 Finally, Axl(+) CD169(+) DCs were present in cancer patients and efficiently captured ganglioside-lip

96 r overall survival (OS) for lung and gastric cancer patients and hence led to the conclusion that BLM

97 ty related to COVID-19 infection in thoracic cancer patients and identified several negative prognost

98 al cell carcinoma and 99 non-small-cell lung cancer patients and identify both conserved trajectories

99 present in more than 60% of newly diagnosed cancer patients and is associated with substantial morbi

100 on rates in biochemically recurrent prostate cancer patients and is positive in about 50% of patients

101 al BPE, BPU, and FGT are decreased in breast cancer patients and may potentially serve as imaging bio

102 with improved long-term survival in gastric cancer patients and merits further focus in surgical qua

103 Metastasis reduces survival in oral cancer patients and pain is their greatest complaint.

104 rom metastatic castration resistant prostate cancer patients and rediscovered recurrent SVs targeting

105 th disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment.

106 known to elicit chronic neuropathic pain in cancer patients and seriously compromise their quality o

107 port centres providing psycho-social care to cancer patients and survivors in Ireland.

108 y correlated with the survival rate of colon cancer patients and that depletion of talin1 inhibited 3

109 verexpressed in tumors of a subset of breast cancer patients and that these patients have lower disea

110 sociated with poor outcome in younger breast cancer patients and thus emphasize the central role of g

111 Genomic studies performed in cancer patients and tumor-derived cell lines have identi

112 MSCs could be an effective countermeasure in cancer patients and victims of nuclear accidents but tha

113 ER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.

114 atasets, one simulated and one from a breast cancer patient, and overview all package functionalities

115 ical significance of circulating LDN in lung cancer patients, and further assessed its diagnostic vs

116 ed in high-grade serous carcinoma of ovarian cancer patients, and its expression is even higher in tu

117 he immunosuppression commonly seen in breast cancer patients, and may lead to a new strategy to resto

118 Mortality from COVID-19 in cancer patients appears to be principally driven by age,

119 Cancer patients are at a higher risk for developing infl

120 Because treatments for breast cancer patients are largely designed based on the detect

121 promising therapeutic approach for prostate cancer patients, as it reduces the viability of prostate

122 cted clinical outcomes of ER-positive breast cancer patients, as well as breast cancer metastasis to

123 The purpose of this study is to identify cancer patients at highest risk of fatal heart disease c

124 compared to the general population and other cancer patients at risk of death during the study time p

125 of postoperative pulmonary function in lung cancer patients before tumor resection is essential for

126 nt residue, previously described in a breast cancer patient, both have gain-of-function Rad50 ATP hyd

127 and MCT4 in tissue samples from human breast cancer patients, but not healthy breast tissue.

128 come in tamoxifen treated ER-positive breast cancer patients by repressing estrogen signaling and ind

129 otherapy induces immune-related responses in cancer patients by various mechanisms.

130 The major cause of death in prostate cancer patients can be attributed to metastatic spread o

131 In breast and lung cancer patients, CAR-T cells targeting the tumor-associa

132 In a breast cancer patient cohort coupled with in silico analysis of

133 X-2/FN predicts for poor prognosis in breast cancer patient cohorts.

134 f globin were significantly elevated in oral cancer patients compared to healthy subjects, while the

135 t up-regulation of Cx43 and ADORA1 in breast cancer patients correlated with decreased relapse-free s

136 th and progression, which we addressed using cancer patient data, cell lines, and orthotopic mouse mo

137 Gene expression analysis in cancer patient datasets indicated that ZNF750 and its ta

138 xtensive independent validations on multiple cancer patient datasets obtained from retrospective obse

139 9]) demonstrate the successful use of rectal cancer patient-derived organoids to predict patient resp

140 ethod to profile the proteomes of two breast cancer patient-derived xenograft (PDX) models, quantifyi

141 glyco-, and phospho-proteomics using breast cancer patient-derived xenograft (PDX) tumor samples.

142 A breast cancer patient-derived xenograft showed similar loss of

143 d neratinib resistance in HER2-mutant breast cancer patient-derived xenografts (PDXs) was also associ

144 A significant proportion of breast cancer patients develop bone metastases, but the mechani

145 Up to 40% of lung cancer patients develop brain metastasis, and the median

146 Over 50% of colorectal cancer patients develop resistance after a transient res

147 Approximately one third of cancer patients die due to complexities related to cache

148 Many breast cancer patients do not complete long-term hormonal thera

149 Most cancer patients do not respond to ICT and the availabili

150 a predictive gene expression model (GEM) for cancer patients' drug responses based on gene expression

151 s, tele-oncology has great potential to help cancer patients during COVID-19 and in the future.

152 ce of integrating clinicians, the public and cancer patients early on in the development of these nov

153 The use of liquid biopsies for cancer patients enables the non-invasive tracking of tre

154 was a retrospective analysis of 388 prostate cancer patients enrolled in 5 prospective studies (NCT02

155 d from a cohort of advanced gastrointestinal cancer patients enrolled in a trial with chemotherapy an

156 l tumor-specific oncolytic immunotherapy for cancer patients, especially those resistant to PD-1/PD-L

157 We found that cancer patients expressing higher level of RGN showed si

158 yeloid-derived suppressor cells (MDSCs) from cancer patients extrude their neutrophil extracellular t

159 help to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies.

160 f rare neoantigen-specific memory T cells in cancer patients for studying cellular immune responses a

161 h can robustly discriminate early-stage lung cancer patients from risk-matched controls.

162 enosumab in premenopausal early-stage breast cancer patients from the Phase-II D-BEYOND clinical tria

163 s and endocrinologists identified by thyroid cancer patients from the Surveillance, Epidemiology, and

164 Moreover, in breast cancer patients, GPX8 expression significantly correlate

165 g therapy for the 10% of non-small cell lung cancer patients harboring mutations in SMARCA4/BRG1.

166 However, modulation of gut microbiota in cancer patients has not been investigated in clinical tr

167 usceptibility to and severity of COVID-19 in cancer patients has not been studied in a prospective an

168 are highly toxic, and approximately half of cancer patients have tumors that are either intrinsicall

169 t mutant identified in somatic tissue from a cancer patient highlighted the significance of APE1 exon

170 ed for pathologists to stratify and diagnose cancer patients; however, novel biophysical techniques m

171 00 FTE cells, predominantly from non-ovarian cancer patients, identified 6 FTE subtypes.

172 Examining FOXA1 in ~5,000 breast cancer patients identifies several hotspot mutations in

173 nomic profiling of solid tumors from 131,668 cancer patients, identifying 9434 patients with one or m

174 mune and stromal populations from colorectal cancer patients, identifying specific macrophage and con

175 udies ~7.3 million variants in 84,457 breast cancer patients in relation to breast cancer survival an

176 d test its psychometric properties in rectal cancer patients, in order to ease its use in clinical pr

177 ess, the majority of advanced-stage prostate cancer patients, including those with SPINK1-positive su

178 lipid mediator present in ascites of ovarian cancer patients, induced expression of TNF-alpha mRNA an

179 d the potential to improve stratification of cancer patients into subtypes with distinct survival and

180 r potential of recombinant IgE antibodies in cancer patients is also discussed.

181 primary staging of treatment-naive prostate cancer patients is still under debate.

182 prehensively charted, but the improvement of cancer patient management somewhat lags behind these bas

183 icacy of systemic therapies for personalised cancer patient management.

184 discriminates histopathologically diagnosed cancer patients (n = 10) from non-cancer controls (n = 2

185 didate genes, we examined early-onset breast cancer patients negative for BRCA1 and BRCA2 pathogenic

186 whole-genome sequencing data from two breast cancer patients obtained using two different sequencing

187 ively analyzed overall survival (OS) of lung cancer patients of a tertiary cancer center in Yunnan to

188 , decreased VHL and PBRM1 mutations in renal cancer patients of African origin, and decreased immune

189 in, and decreased immune activity in bladder cancer patients of East Asian origin.

190 ional guidelines with known risk factors for cancer patients, offers a case-based discussion for revi

191 We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other antic

192 AT3 inhibitor, on CSCs derived from prostate cancer patients, on docetaxel-resistant spheres with ste

193 ree DNA, isolated from the blood of prostate cancer patients, on non-tumor prostate cell lines (RWPE-

194 colon cancer and resected tumors from colon cancer patients, our data demonstrated that HT-DBP could

195 ole of steroid hormones in female colorectal cancer patients, our findings suggest a tumor-suppressiv

196 a novel targeted therapy option in cervical cancer patients overexpressing Trop-2.

197 Compared to other cancer patients, patients who are older, male, African A

198 Methods: Seventy-five non-small cell lung cancer patients planned for lobectomy were prospectively

199 assay plasma samples from an additional 223 cancer patients, plus 200 primary tumor and normal tissu

200 ng cell-free tumor DNA amounts in blood from cancer patients possible.

201 from smoking to overall survival among lung cancer patients potentially mediated by 365,307 DNA meth

202 In breast cancer patients, PREX1 levels are significantly increase

203 The signature identified cancer patients prior to a clinical diagnosis and was su

204 A germline BRCA mutation (BRCAm) in ovarian cancer patients provides prognostic and predictive infor

205 Conclusion: For treatment-naive prostate cancer patients, PSMA PET/CT is well suited for the dete

206 Cancer patients receive numerous medications not only to

207 tics (PK) data of the OPTILIV trial in which cancer patients received oxaliplatin, 5-fluorouracil and

208 phil phenotype was also observed in prostate cancer patients receiving androgen deprivation therapy,

209 The emerging outcomes of clinical trials of cancer patients refractory to all other treatments provi

210 Os to predict responses to chemoradiation in cancer patients remains an open question.

211 We included 752 operable stage I-III breast cancer patients representing all subtypes treated from 2

212 Making decisions on how best to treat cancer patients requires the integration of different da

213 ld be exploited to afford neuroprotection in cancer patients requiring treatment with oxaliplatin.

214 a variety of cancers, but only a minority of cancer patients respond.

215 uencing of freshly isolated CTCs from breast cancer patients revealed a subset with strong ribosome a

216 f-principle, we apply MutSpace to 560 breast cancer patient samples and demonstrate that our method a

217 In cancer patient samples, RITA, AF, and Onc-1 sensitized t

218 lmanocept in a heterogeneous group of breast cancer patients scheduled for SLN biopsy.

219 Analysis of 130 prostate cancer patient serum samples revealed that some members

220 guidelines for bone assessments in prostate cancer patients should be revisited because (68)Ga-PSMA-

221 d ewes on a schedule similar to that used in cancer patients showed extensive suppression of bone rem

222 ons and suggest additional possibilities for cancer patients' stratification and for the development

223 Here we report that 394,849 of the 7,529,481 cancer patients studied died of heart disease.

224 e assessment in anticipation of human breast cancer patient studies.

225 the protein expression of YTHDF1 in ovarian cancer patients, suggesting modification of EIF3C mRNA i

226 lternative splicing of CLSTN1 predict breast cancer patient survival.

227 ments (mitochondrial memory) and renders the cancer patient susceptible to subsequent regimens of dru

228 highlight new therapeutic opportunities for cancer patients that are not sensitive to HER2 antagonis

229 ght loss and anorexia are common symptoms in cancer patients that occur prior to initiation of cancer

230 In renal and lung cancer patients, the presence of the enterococcal propha

231 sease-like configuration occur in colorectal cancer patients, thereby masking disease signatures.

232 potentially impacts RT treatment outcome in cancer patients through IR-induced DNA damage responses.

233 IL8 levels positively correlated in ovarian cancer patient tissue.

234 CRISPR activation screen in CTCs from breast cancer patients to identify genes that promote distant m

235 has been emphasized in research on terminal cancer patients to increase the quality of end-of-life c

236 entions for adult non-central nervous system cancer patients to manage cancer-related cognitive impai

237 trospective analysis of consecutive advanced cancer patient treated with PD-1/PD-L1 checkpoint inhibi

238 A metastatic prostate cancer patient treated with the PARP inhibitor talazopar

239 g hospital release of differentiated thyroid cancer patients treated with (131)I since the publicatio

240 of epigenetic priming in ER-positive breast cancer patients treated with checkpoint inhibitors as pr

241 Lung cancer patients treated with CPIs combined with CC have

242 valuated the incidence of infections in lung cancer patients treated with CPIs plus conventional chem

243 sociated with shortened survival in advanced cancer patients treated with PD1/PDL1 checkpoint inhibit

244 In rectal cancer patients treated with SC-TNT and proctectomy, we

245 signature in early-stage non-small cell lung cancer patients treated with stereotactic body radiother

246 Breast cancer patients treated with tamoxifen may experience re

247 predict tumor response for two HER2 + breast cancer patients treated with the same therapeutic regime

248 tease activities was characterized in breast cancer patient tumor samples.

249 High-grade serous ovarian cancer patient tumors and cells express significantly hi

250 n patterns between the PDXs and pretreatment cancer patient tumors.

251 o detect synchronous primary malignancies in cancer patients undergoing a staging workup.

252 y and persistent postoperative opioid use in cancer patients undergoing curative-intent surgery.

253 of persistent postoperative opioid use among cancer patients undergoing curative-intent surgery.

254 and feasible strategy to improve efficacy in cancer patients undergoing radiation therapy.

255 bility of imaging tumor metabolism in breast cancer patients using (13)C magnetic resonance spectrosc

256 genomic alterations and mRNA expression from cancer patients using available data from The Cancer Gen

257 d tumor and normal organoids from two breast cancer patients using Illumina/10x Genomics, Pacific Bio

258 s a pathway shown to be dysregulated in oral cancer patients, using gene therapy and repurposing an a

259 High SLUG expression in tumors of lung cancer patients was associated with poor survival.

260 In breast and pancreatic cancer patients we find that low FAK expression, specifi

261 ta from in vitro experiments and in prostate cancer patients, we found that a significant number of A

262 tumor samples from 14 prostate and pancreas cancer patients, we identify subclonal CNAs and WGDs tha

263 2015 to April 2019, 100 consecutive advanced cancer patients were evaluated.

264 astric, 15,908 pancreatic, and 21,354 rectal cancer patients were included of which 61.1%, 21.2%, and

265 GENs) to therapeutically edit RNA and DNA in cancer patients were recently published.

266 Treatment-naive breast cancer patients were recruited: four triple-negative gra

267 Annual mortality rates among breast cancer patients were significantly greater in LMICs in S

268 rable prognostic value in a cohort of breast cancer patients, where it predicted high probability of

269 gitudinal blood plasma samples from prostate cancer patients, where longitudinal tissue biopsies from

270 ere determined in serum of postprostatectomy cancer patients which had much lower levels than prostat

271 ed with better overall survival among breast cancer patients, while high fruit juice consumption may

272 iomarker that is able to identify colorectal cancer patients who are responding to anti-angiogenic tr

273 l Cancer Database was queried for pancreatic cancer patients who underwent pancreaticoduodenectomy.

274 To protect cancer patients whose survival depended on timely surger

275 hile the majority of advanced-stage prostate cancer patients will initially respond to the androgen d

276 gest overall survival reported in colorectal cancer patient with nonresectable liver metastases.

277 ate and high cell-cycle activity in 9515 pan-cancer patients with 32 different tumour types.

278 g the CT and PET parts of 28 PET/CT scans of cancer patients with 40 lesions up to 3 cm in size in th

279 infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy.

280 ocentric study was conducted on 135 prostate cancer patients with biochemical recurrence and a PSA le

281 ed pathogenic events are likely magnified in cancer patients with COVID-19.

282 We examined 281 lung cancer patients with distant metastasis and found that s

283 ors may provide improved outcomes for breast cancer patients with drug-resistant metastatic disease.

284 uctions of tumor phylogenies in ten prostate cancer patients with fatal disease, and investigate them

285 egative breast cancer (TNBC) and 1365 breast cancer patients with information on neoadjuvant chemothe

286 abase indicates that KRAS mutated colorectal cancer patients with low intratumor ferritin mRNA levels

287 e a potential effective treatment for breast cancer patients with metastatic disease.

288 tive (SECA-II) study, we included colorectal cancer patients with nonresectable liver-only metastases

289 A total of 23,168 breast cancer patients with positive hormone receptor (HoR) wer

290 and could be a better choice for male rectal cancer patients with specific staging and location TRIAL

291 However, treatment of advanced pancreatic cancer patients with STAT3 inhibitors often meets drug r

292 ociation between PMRT and outcomes in breast cancer patients with T1-2 tumors and 1-3 positive lymph

293 to evaluate oncological outcomes for breast cancer patients with T1-2 tumors and 1-3 positive lymph

294 als and are a promising therapy for prostate cancer patients with TMPRSS2-ERG fusions and mutations i

295 While breast cancer patients with tumors that express estrogen recept

296 rtoire sequencing studies conducted on human cancer patients, with a focus on studies of the T-cell r

297 s which proportions are markedly modified in cancer patients, with CD66b(+) /CD10(low) /CXCR4(+) /PDL

298 c tool, we analyzed the plasma of 20-bladder cancer patients without any sample processing steps.

299 ts which had much lower levels than prostate cancer patients without surgery.

300 ng from checkpoint blockade immunotherapy in cancer patients, yet the underlying mechanisms for such